Work on new UK value-based pricing system to start next April
This article was originally published in Scrip
Executive Summary
As part of sweeping reform planned for the National Health Service in England, the UK coalition government is to begin developing a new value-based pricing strategy for drugs next April, and plans to create a new Cancer Drugs Fund in the same month. The reforms also involve an overhaul of the way in which healthcare services are commissioned.
You may also be interested in...
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.